Tharimmune, Inc. (Nasdaq:THAR) (”Tharimmune” or the “Company”), a clinical-stage biotechnology company focused on immunology and inflammation, today announced positive preclinical results for its ...
Patients with skin disease adhering to a proper diet may experience better treatment responses and a reduced risk of adverse ...
BRIDGEWATER, NJ / ACCESS Newswire / March 24, 2025 / Tharimmune, Inc. (Nasdaq:THAR) ("Tharimmune" or the "Company"), a clinical-stage biotechnology company focused on immunology and inflammation ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback